Hematology Oncology of Indiana and American Oncology Network Welcome Dr. Amy Braden

Rhea-AI Summary

Hematology Oncology of Indiana (AONC) announced that Dr. Amy Braden, DO, a board-certified medical oncologist and hematologist with over 10 years of experience, has joined its physician team and is accepting new patients as of February 3, 2026. Dr. Braden will see patients in Indianapolis, Logansport, and Noblesville.

The practice operates six locations across Indiana and offers specialty infusion, pathology, pharmacy, clinical trials, and BiTE therapy as part of community-based cancer care.

Key Figures

Current price: $11.50 52-week range: $0.0004–$14.25 Annual revenue: >$2 billion +5 more

8 metrics

Current price $11.50 Pre-news trading level for AONC

52-week range $0.0004–$14.25 52-week low to high for AONC

Annual revenue >$2 billion 12 months ended June 30, 2025

Revenue growth >40% Year-over-year for 12 months ended June 30, 2025

CMS cost savings $6 million Value-based care performance reported Aug 12, 2025

Commercial savings $2.7 million Value-based care performance reported Aug 12, 2025

Partner income lift 30% increase Average sustainable income increase after joining AON

BiTE therapy clinics 40+ clinics Sites offering bispecific T-cell engager therapies as of Aug 12, 2025

Market Reality Check

Price: $12.00 Vol: Volume 110 is about 0.08x...

low vol

$12.00 Last Close

Volume Volume 110 is about 0.08x the 20-day average of 1344, indicating very light trading ahead of this news. low

Technical Shares at $11.50 are trading above the 200-day MA of $8.87 and about 19.3% below the 52-week high of $14.25.

Peers on Argus

While AONC is down about 4.17%, key peers show mixed moves: WHTCF (-0.99%), HWAI...

While AONC is down about 4.17%, key peers show mixed moves: WHTCF (-0.99%), HWAIF (-3.42%), HLYK (-8.38%), ATIP (0%), and NUMIF (+17.08%). This mixed pattern and an empty momentum scanner suggest stock-specific trading rather than a clear sector-wide move.

Historical Context

5 past events · Latest: Jan 21 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 21	Staff additions	Positive	-36.6%	Genesis Cancer and Blood Institute adds endocrinologist and nurse practitioner in Arkansas.
Oct 10	Research presentations	Positive	-1.5%	Fifteen AON research abstracts accepted for ASCO Quality Care Symposium 2025.
Oct 07	Physician hire	Positive	+0.3%	AON and CCBD welcome board-certified medical oncologist Dr. Chitra Rajagopal in Maryland.
Sep 02	Physician expansion	Positive	+2.8%	Genesis Cancer and Blood Institute adds Dr. Beau Hilton to its 11-location Arkansas network.
Aug 12	Growth update	Positive	+2.0%	AON reports >$2B annual revenue, >40% growth, and expanded therapies and providers.

Pattern Detected

Recent AONC headlines have been largely positive practice-expansion and growth updates, yet price reactions are mixed, with several staffing and research announcements followed by negative moves, while broader growth milestones tended to align with modest gains.

Recent Company History

Over the past six months, American Oncology Network has focused on expanding its community oncology footprint and highlighting growth. On Aug 12, 2025, it reported annual revenue above $2 billion with over 40% year-over-year growth and more than 300 providers across 20 states. Subsequent releases on new physician additions in Arkansas and Maryland, and research visibility at ASCO Quality 2025, reinforced a growth and access story. Today’s Indiana physician addition fits this pattern of network and clinical capability expansion.

Market Pulse Summary

This announcement highlights continued expansion of American Oncology Network’s community-based onco...

Analysis

This announcement highlights continued expansion of American Oncology Network’s community-based oncology capabilities, adding a board-certified oncologist and hematologist to Hematology Oncology of Indiana’s multi-site practice. In context, AON previously reported annual revenue above $2 billion, over 40% growth, and more than 300 providers across 20 states. Investors may monitor how additional specialists, advanced therapies like BiTE treatments, and value-based care performance translate into sustained growth and operational efficiency.

Key Terms

hematology, oncology, osteopathic medicine, clinical trials, +3 more

7 terms

hematology medical

"Dr. Braden is a Board-certified medical oncologist and hematologist with more than..."

Hematology is the branch of medicine that studies blood, its components (like red and white cells and platelets), and disorders that affect them. For investors, it matters because treatments, diagnostics, and devices that diagnose or fix blood problems can drive sales, regulatory risk, and patent value—think of it as investments in the maintenance and repair of the body's delivery system, where breakthroughs or setbacks can quickly change a company's prospects.

oncology medical

"Hematology Oncology of Indiana (HOI) and American Oncology Network (AON)..."

Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.

osteopathic medicine medical

"She earned her Doctorate of Osteopathic Medicine degree from Nova Southeastern University..."

Osteopathic medicine is a branch of medical care led by fully licensed physicians who combine standard medical diagnosis and treatment with extra training in whole‑person care and hands‑on techniques to help the body heal itself, similar to adding a manual toolkit to a doctor’s skillset. Investors care because osteopathic physicians are a growing part of the healthcare workforce, influence patient referral patterns, reimbursement and service demand, and can affect staffing, costs and revenue across hospitals, clinics and insurers.

clinical trials medical

"The practice offers a full range of exceptional cancer services, including ... clinical trials and BiTE therapy..."

Clinical trials are carefully controlled studies that test whether a new drug, device or treatment is safe and effective in people, moving through successive stages that increase the number of participants and the rigor of testing. Investors care because trial outcomes determine whether a product can be approved and sold, shaping a company’s future revenue, valuation and risk profile—think of it as proof-of-concept testing that decides if a prototype becomes a market-ready product.

endocrinology medical

"The hires expand Genesis to offer onsite endocrinology alongside oncology across 11 Arkansas locations..."

Endocrinology is the branch of medicine that studies hormones, which are chemicals produced by glands in the body that regulate important functions like growth, energy, and mood. Understanding how hormones work can reveal insights into health conditions and overall well-being. For investors, it highlights areas of medical research and pharmaceutical development that may influence healthcare trends and market opportunities.

bispecific t-cell engager therapies medical

"Key achievements include the launch of bispecific T-cell engager therapies in 40+ clinics..."

Bispecific T‑cell engager therapies are drugs engineered to attach to two different targets at once: one on a cancer or diseased cell and one on a patient’s T cell, bringing them together so the immune cell can kill the target. Think of them as a matchmaker that forces a trained fighter to confront a hidden enemy. Investors watch them because they can offer powerful, targeted treatments with large market potential but carry high development risk, regulatory hurdles and safety concerns that can sharply affect company value.

value-based care financial

"The company demonstrated strong value-based care performance, achieving $6 million in CMS cost savings..."

A health-care delivery approach that rewards providers for keeping patients healthy and improving outcomes instead of charging for each test or visit. For investors, it matters because it shifts where profits and losses come from—favoring providers and technologies that lower long-term costs, prevent complications, and demonstrate measurable results; think of it like paying a contractor only when the house stays sound, which changes who wins and loses financially.

AI-generated analysis. Not financial advice.

INDIANAPOLIS, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Hematology Oncology of Indiana (HOI) and American Oncology Network (AON), one of the nation’s fastest-growing networks of community-based oncology practices, is pleased to announce that Amy Braden, DO, has joined the practice’s physician team and is now accepting new patients.

Dr. Braden is a Board-certified medical oncologist and hematologist with more than 10 years of experience in patient care. She earned her Doctorate of Osteopathic Medicine degree from Nova Southeastern University in Fort Lauderdale, Florida. She then completed her internal medicine residency at the Medical College of Wisconsin in Milwaukee, followed by a hematology and oncology fellowship at the University of Wisconsin in Madison.

“I am thrilled to join Hematology Oncology of Indiana,” said Dr. Braden. “The practice has a long-standing reputation for delivering the high-quality, patient-centered community cancer care that I value, and I look forward to collaborating with the physician team to continue delivering exceptional care to patients in Indiana.”

“We are pleased to welcome Dr. Braden to Hematology Oncology of Indiana,” said Brian P. Mulherin, MD, a Board-certified hematologist and oncologist at the practice. “Her impressive background and dedication to personalized care make her an excellent addition to our team. I’m confident our patients and physicians will benefit from her extensive knowledge and expertise.”

HOI provides high-quality community-based cancer care at six locations, including two practices in metropolitan Indianapolis, and additional locations in Logansport, Lebanon, Noblesville, and Fishers, Indiana. The practice offers a full range of exceptional cancer services, including specialty infusion services, pathology, pharmacy, clinical trials and BiTE therapy, providing treatment based on research and focused on the whole person.

“On behalf of AON, I’m excited to welcome Dr. Braden to Hematology Oncology of Indiana and to our national network,” said Stephen “Fred” Divers, MD, AON’s chief medical officer. “Her clinical expertise and commitment to delivering exceptional, patient-centered community-based cancer care will strengthen the care we offer in Indiana and across the network.”

Dr. Braden is now seeing patients at Hematology Oncology of Indiana’s Indianapolis, Logansport, and Noblesville locations.

For more information about American Oncology Network, visit www.AONcology.com. For more information about Hematology Oncology of Indiana, visit www.hematologyoncologyin.com.

About American Oncology Network
American Oncology Network (AON) is an alliance of physicians and seasoned healthcare leaders partnering to ensure the long-term success and viability of community oncology and other specialties. Founded in 2018, AON’s rapidly expanding network represents more than 300 providers practicing across 20 states. AON pioneers innovative healthcare solutions through its physician-led model, fostering value-based care that improves patient outcomes while reducing costs and expanding access to quality care. AON equips its network physicians with the tools they need to thrive independently while providing comprehensive support, integrated revenue-diversifying ancillary services, and practice management expertise, enabling physicians to focus on what matters most – providing the highest standard of care for every patient. AON is committed to promoting health equity by addressing disparities in cancer care and ensuring that all patients have access to the care they need to achieve optimal health outcomes. With a focus on innovation and collaboration, AON is shaping the future of community oncology. For more information, please visit AONcology.com or follow us on LinkedIn, Facebook, X (formerly Twitter) and YouTube.

About Hematology Oncology of Indiana

Hematology Oncology of Indiana is a community-based medical oncology and hematology practice providing treatment for patients diagnosed with all types of cancer and blood disorders. Through compassionate care that centers around the patient, Hematology Oncology of Indiana strives to provide the best possible experience to patients and their families throughout the healthcare journey. Learn more at hematologyoncology.com.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/00b9051a-b8b0-415b-98d2-c0ea49875a8e

Contact:
Karen Riley Sawyer
American Oncology Network
Karen.Sawyer@AONcology.com

FAQ

Who is Dr. Amy Braden and what is her role at Hematology Oncology of Indiana (AONC)?

Dr. Amy Braden is a board-certified medical oncologist and hematologist joining Hematology Oncology of Indiana's physician team. According to the company, she has more than 10 years of clinical experience and will provide patient care at several Indiana locations, accepting new patients starting February 3, 2026.

Which AONC locations will Dr. Amy Braden be seeing patients at in 2026?

Dr. Braden will see patients at Hematology Oncology of Indiana's Indianapolis, Logansport, and Noblesville locations in 2026. According to the company, these sites are part of the practice's six Indiana locations offering community-based oncology services.

What clinical services does Hematology Oncology of Indiana offer that AONC patients can expect?

Hematology Oncology of Indiana offers specialty infusion, pathology, pharmacy, clinical trials, and BiTE therapy as part of care. According to the company, these services support research-based, whole-person community cancer care across its six Indiana locations.

How does Dr. Braden's background qualify her for her role at AONC?

Dr. Braden earned a DO degree and completed residency and fellowship training in internal medicine, hematology, and oncology. According to the company, her training at Nova Southeastern University, Medical College of Wisconsin, and University of Wisconsin underpins her clinical expertise and patient-centered approach.

How can patients schedule appointments with Dr. Amy Braden at AONC in February 2026?

Patients can contact Hematology Oncology of Indiana to schedule appointments with Dr. Braden at the Indianapolis, Logansport, or Noblesville offices. According to the company, Dr. Braden is now accepting new patients and appointment details are available via the practice's website and contact channels.